jcru

Journal of Cancer Research Updates

About a Rare Case of Low-Grade Chondrosarcoma of the Cranial Vault - Pages 35-40

Leonello Tacconi, Gennaro D’Acunzi, Camilla Russo, Andrea Manto, Ginevra F. D’Onofrio and Raffaele Fristachi

DOI: http://dx.doi.org/10.6000/1929-2279.2018.07.02.1

Published: 16 May2018


Abstract: Chondrosarcoma is a rare malignant tumour arising from the cartilage with a high variability in the clinical course and overall prognosis. 
This entity has, generally, a predilection for long bones of the limbs and pelvis and the location in the cranial bones is quite rare. We report a case of a 38 year male with a large and poorly symptomatic parafalcine chondrosarcoma of the cranial vault which was removed en bloc. The described location is extremely rare. Magnetic Resonance Imaging permitted to better delineate the lesion and plan the most appropriate therapeutic approach. Final diagnosis was based on histological examination, which confirmed the hypothesis of low-grade parafalcine chondrosarcoma. Even though surgery remains the mainstay of treatment for cerebral chondrosarcomas, adjuvant radiotherapy such as stereotactic, proton beam or carbon ion-beam therapy might be necessary in aggressive or incomplete removed cases. 

Keywords: Chondrosarcoma, Computed Tomography, Magnetic Resonance Imaging, skull base, malignant tumor, adjuvant radiotherapy.

Download Full Article

Journal of Cancer Research Updates

Study of the Prevalence and the Incidence of the Prostate Cancer in the North-Cameroon: Means and Costs of Management - Pages 41-48

Herve Kada Pabame, Armel Herve Nwabo Kamdje, Richard Tagne Simo and Franklin Danki Sillong

DOI: http://dx.doi.org/10.6000/1929-2279.2018.07.02.2

Published: 16 May2018


Abstract: Introduction: The high mortality rate of prostate cancer in Cameroon, its high incidence, its prevalence, the lack of epidemiological data for the north which for the case is the poorest area of the country led us to conduct this study with for the purpose of presenting the epidemiological, clinical and para-clinical aspects, the cost and means of management with a view to setting up adequate management policies.

Patients and Methods: We conducted a cross-sectional analytical study in the city of Ngaoundéré for a period of 5 months. The data were obtained after a survey of patients and collection of results from the pathology registry of the Islamic clinic of Adamawa three months before the start of our study.

Results: The prevalence and incidence of prostate cancer were 28.7% and 24.32%, respectively. The average age of prostate cancer patients was 66.5 years. Gleason scores were less than 6 in 44.44% of cases. Risk factors related to familial cancer cases were difficult to determine. The symptoms were dominated in patients by urinary retention associated with polyuria, dysuria and pollakiuria. The means and costs of care were scalable depending on the difficulty of achieving the technique.

Conclusion: Prostate cancer remains a real health problem in the north because of its incidence and high prevalence and requires the implementation of a government policy of care.

Keywords: Cancer, prostate, Cameroon, epidemiology.

Download Full Article

Journal of Cancer Research Updates

Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML - Pages 49-58

Atish Patel, Hui Zhang, Deshen Wang, Dong-Hua Yang, Sanjay Dholakiya and Zhe-Sheng Chen

DOI: http://dx.doi.org/10.6000/1929-2279.2018.07.02.3

Published: 16 May2018


Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic stem cells. Identifying the leading mutation in BCR-ABL that causes CML made it possible to develop a targeted approach against this vastly disseminating disease. The active tyrosine kinase protein of BCR-ABL was effectively blocked with an identified tyrosine kinase inhibitor (TKI), imatinib. Imatinib became the first targeted therapy licensed for patients with chronic-phase CML and its introduction was associated with substantial improvements in response and survival compared with previous therapies. However, drug resistance towards imatinib therapy soon emerged and hence limited the complete eradication of CML in patients receiving imatinib. This is primarily due to the mutations within the ABL kinase domain, and to a lesser degree, due to residual disease after treatment. Nilotinib and dasatinib were soon introduced and showed improved clinical outcomes in patients intolerant and resistant to imatinib treatment. However, the T315I mutant overcame these agents along with imatinib, rendering the treatment ineffective. Exploring the kinase domain of the BCR-ABL protein and identifying key components involved in the signal transduction pathways is crucial towards understanding the disease and developing better strategic approaches towards combating it. In this review, we broadly discuss the current treatment options available against Philadelphia chromosome (Ph) positive BCR-ABL CML. 

Keywords: BCR-ABL, tyrosine kinase, imatinib, nilotinib, dasatinib.

Download Full Article

Journal of Cancer Research Updates

Sildenafil Induces Cell Cycle Arrest and Apoptosis in Human Colorectal Cancer HT-29 Cells - Pages 59-63

Wu-Ming Qin, Kun Wang, Jia-Rong Huang, Xiao-Long Mei and Zhi Shi

DOI: http://dx.doi.org/10.6000/1929-2279.2018.07.02.4

Published: 7 June2018


Abstract: Phosphodiesterase is an enzyme that degrades the phosphodiester bond in the second messenger molecules cAMP and cGMP, and regulates the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. Sildenafil is a potent and selective inhibitor of the type 5 cGMP-specific phosphodiesterase used clinically to treat erectile dysfunction and pulmonary arterial hypertension. In this study, we examined the effect of sildenafil on human colorectal cancer HT-29 cells. Our data showed that sildenafil induced cell cycle arrest and apoptosis, and cotreatment with a ROS scavenger N-acetyl-L-cysteine partially reversed cell apoptosis caused by sildenafil in human colorectal cancer HT-29 cells. Overall, our study suggests that sildenafil appears to be a promising new treatment option for colorectal cancer. 

Keywords: Sildenafil, Colorectal cancer, Cell Cycle, Apoptosis.

Download Full Article